Skip to main content
NEWLAND PHARMACEUTICAL CO., LTD logo

NEWLAND PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 301277 ISIN · CNE1000065K2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 481 across all filing types
Latest filing 2023-11-02 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 301277

About NEWLAND PHARMACEUTICAL CO., LTD

https://www.newlandpharma.com

Newland Pharmaceutical Co., Ltd. is a specialized enterprise engaged in the research, development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs) and high-quality chemical intermediates. The company focuses on a broad spectrum of therapeutic categories, including cardiovascular, anti-infective, and metabolic health solutions. Operating with a commitment to rigorous quality control, its production facilities are designed to meet international Good Manufacturing Practice (GMP) standards. Newland Pharmaceutical prioritizes technological innovation and chemical synthesis optimization to deliver reliable pharmaceutical components. Its core operations involve the large-scale production of complex molecules, supporting the supply chains of healthcare providers and pharmaceutical formulators worldwide through a focus on technical excellence and regulatory compliance.

Recent filings

Filing Released Lang Actions
2023年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the "2023 Fourth Extraordinary General Meeting of Shareholders" of Xintiandi Pharmaceutical Co., Ltd. It details the meeting date, voting procedures, attendance, and the voting results on specific proposals. It also includes a legal opinion from a law firm confirming the legality of the meeting and its resolutions. The document does not contain financial statements or detailed financial analysis, nor is it a transcript or presentation. It is an official announcement of the voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is 2338 characters, which is consistent with an announcement rather than a full report.
2023-11-02 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about receiving an approval notice from the National Medical Products Administration for a chemical raw material drug listing application. It details the drug information, approval details, and potential impact on the company. The document is short (1068 characters) and serves as a formal notification of regulatory approval rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or other report content. Therefore, it fits best as a Regulatory Filing (RNS), which is a general regulatory announcement category for filings that do not fit other specific categories.
2023-10-26 Chinese
关于获得化学原料药上市申请批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about receiving an official approval notice from the National Medical Products Administration for the listing of a chemical raw material drug (Lidocaine). It includes details about the approval notice, drug information, and the impact on the company. The document is short (1153 characters) and serves as an announcement of a regulatory approval rather than a financial report or detailed filing. It does not contain financial data, management changes, or voting results. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a material event that does not fit other specific categories.
2023-10-18 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第三季度报告' which translates to '2023 Third Quarter Report'. It contains detailed financial data including revenue, net profit, cash flow, assets, liabilities, and shareholder information for the third quarter of 2023. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year indicates this is an Interim / Quarterly Report. The document length is substantial (15,000 characters) and contains actual financial data, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2023
2023-10-15 Chinese
第五届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 5th Board of Directors of the company 新天地药业股份有限公司. It includes approval of the 2023 Q3 report, appointment of a board secretary, revisions to governance documents, and scheduling of a shareholders meeting. The text references voting results and meeting procedures, typical of board meeting minutes or resolutions. It does not contain the full quarterly report or detailed financial statements but refers to the report being separately disclosed on a website. The document is under 5,000 characters and serves as an announcement of board decisions and governance updates rather than the report itself. Therefore, it fits best under Board/Management Information (MANG).
2023-10-15 Chinese
关于2023年第三季度报告披露的提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (264 characters) indicating that the company's 2023 third quarter report has been published and is available on a website. It does not contain the actual financial data or substantive analysis from the report itself, but rather directs investors to where the report can be found. According to the 'MENU VS MEAL' rule, such a brief notice that a report is published and available is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2023-10-15 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.